Advantages of modified drug delivery system in psychiatry

Anant D. Patil*

ABSTRACT

Non-compliance is a common problem in chronic diseases including psychiatric disorders. Various attempts have been made for improving adherence in psychiatry; one of them being simplifying dosage regimen by designing modified dosage formulation. For example, depot formulation, oral disintegrating tablets or extended release formulations are some of the strategies for improving compliance in psychiatry patients. Modified dosage formulations also have some other advantages too. For example, oral disintegrating tablet of olanzapine cause lesser weight gain compared to standard olanzapine tablet while Zolpidem extended release tablet provides better sleep maintenance in middle of night. This article reviews some of the modified dosage formulations in psychiatric diseases with their advantages.

Keywords: Psychiatry, Dosage form, Compliance, Advantages

INTRODUCTION

Non-adherence to medicine is an issue in psychiatry. High rates of non-compliance have been reported in psychiatric disorders; 28% - 52% for major depressive disorder, 20%- 50% for bipolar disorder, and 20% - 72% for schizophrenia.¹ Non-compliance is one of the commonest causes of failure to achieve desired therapeutic response. It is not surprising to have more non-compliance in psychiatric diseases compared to other medical conditions. The issue of non-compliance in psychiatry diseases has been discussed since many decades. In one of the articles published more than 30 years before Seltzer A and Hoffman BF (1980) discussed compliance issues in psychiatric patients. In this article authors have discussed various reasons of non-compliance in psychiatry patients and also suggested some measures for improvement of compliance. Simplification of dosage regimen is one of the suggested measures in improving adherence in psychiatry patient.

Even today despite of having many drugs and different formulations, non-compliance in psychiatry patients still continues. A recently published study (2013) from Qatar, examined the prevalence and reasons for non-compliance in psychiatry out patients. Out of 564 patients, 41.8% were found to be non-compliant. Common diseases reporting non-compliance were schizophrenia (28.4%), depression (14.4%), and bipolar affective disorder (12.7%). Poor family support, irregular attendance to clinic, ignorance about side effects of drugs, free medicines, and a lack of education about drug were commonly reported reasons for non-compliance in these patients.³

Simple regimen and modified dosage forms help to improve patient compliance and adherence to treatment. They also help to improve patient outcome. In management of psychiatric diseases various modified release formulations are used; some of them have objective of improving patient compliance while others have different advantages. Modified drug delivery systems used in psychiatric disorders and their advantages are discussed below.

MODIFIED DRUG FORMULATION IN BIPOLAR DISORDER

Divalproex sodium extended release tablets

Divalproex is available in delayed release as well as extended release formulation. Delayed release and extended release formulations are not bioequivalent. For conversion from delayed release to extended release
formulation, dose of extended release may need to be increased between 8%–20% for achieving equivalent serum concentration. The extended-release tablet of divalproex sodium provides advantages of a once-daily administration. Other advantage of the extended release divalproex sodium is controlled and continued release of divalproex sodium from the tablet. Extended release formulation results in less fluctuation in the peak serum concentration compared to delayed release formulation.4

MODIFIED DOSAGE FORMULATIONS IN SCHIZOPHRENIA

Olanzapine mouth dissolving tablets

Olanzapine is an effective and well-tolerated atypical antipsychotic used in the treatment of schizophrenia. Oral disintegrating olanzapine is available as an alternative to standard oral tablets of olanzapine. Orally disintegrating tablet rapidly disintegrates and dissolves in saliva. This formulation is convenient to patient and helps to enhance adherence to treatment. Patient preference and reduction in nursing burden are the other advantages with oral disintegrating tablets of olanzapine.5 Limitations for use of olanzapine include risk of the adverse events like weight gain, dyslipidemia and diabetes. Olanzapine oral disintegrating tablets have an advantage over standard tablet in this regard. Oral disintegrating tablets of olanzapine cause less weight gain. An open label prospective study in India determined the change in weight after switching from olanzapine standard tablet to olanzapine mouth dissolving tablet in 30 patients. These patients were switched to equivalent doses of oral disintegrating tablets from oral standard tablet of olanzapine. Evaluation of weight was done at baseline and at 4, 8, and 12 weeks. Following figure (Figure 1) shows % of patients with weight changes.6 The mean loss of weight reported was 1.9 ± 0.3 kg.

Paliperidone extended release

Schizophrenic patients lack insight. This is one of the challenges in the effective treatment and one of the causes for nonadherence in schizophrenia. Due to these reasons there is always an interest in developing drugs with once daily dosage or depot preparation with objective of improving adherence to treatment. Paliperidone is active metabolite of risperidone and available as paliperidone extended-release formulation.7

Risperidone depot formulation

Long-acting depot formulation of the second-generation antipsychotic drug risperidone is available for the treatment of schizophrenia. With this formulation, the treatment regimen for risperidone is simplified. Intramuscular depot injection of risperidone is administered every two weeks.8

Asenapine sublingual tablet

Asenapine is another antipsychotic used in the treatment of schizophrenia. It is not available as standard oral tablet. Asenapine is available as a sublingual fast dissolving tablet. The challenge in developing oral tablet of asenapine is it’s high hepatic first pass metabolism9. Sublingual administration with asenapine is required because bioavailability is very less if it is ingested (<2%).10

MODIFIED DOSAGE FORMULATION FOR INSOMNIA MANAGEMENT

Zolpidem extended release formulation for treatment of Insomnia

Patients suffering from Insomnia have difficulty in initiation or maintenance of sleep or wake up very early or may have combination of these symptoms. Zolpidem is GABA A receptor agonist which preferentially binds to alpha 1 subunit of receptor complex. It is used in short term management of Insomnia. Zolpidem extended release tablet is a dual-layer tablet. One layer releases zolpidem immediately while other layer releases it slowly. The objective of designing this formulation is treatment of both sleep onset and sleep maintenance insomnia. Zolpidem extended release 12.5 mg tablet provides fast onset of action which helps for sleep induction but helps in better maintenance of sleep in middle of night. The profile of adverse events is similar to immediate release zolpidem tablet.11 Thus in zolpidem extended release formulation the objective of modified drug release is not improving compliance, but to provide better sleep maintenance in middle part of the night. A Multicenter, randomized, double-blind, placebo-controlled, study with zolpidem extended-release 12.5 mg up to 6 months showed sustained and significant improvements in both sleep onset as well as sleep maintenance.12

Figure 1: Percentages of patients with weight changes.
CONCLUSION

Non-adherence to medicines is one of the challenges in management of psychiatric disorders. Various strategies are used for increasing adherence to medical treatment; one of them being using simplified dosage regimen. Drug formulation modifications like extended release formulation, depot formulation, mouth dissolving formulation help to improve patient compliance. In addition to improving adherence, some formulations also have other advantages which help to improve outcome of treatment in psychiatric diseases.

Funding: None
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES
